Canaan IX L.P. is Director & 10% Owner at CytomX Therapeutics, Inc. (CTMX). They have made 11 open-market trades across 1 company since 2016, most recently 2020-01-14.
CIK 0001501989
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 55% | 36% | 0% |
| Avg Move | -0.6% | +0.4% | +12.7% |
| Scored | 11 | 11 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTMX | SELL | 2016-11-23 | 2016-11-28 | $11.56 | $444K | +8.1% | +0.4% | +9.2% |
| CTMX | SELL | 2016-11-22 | 2016-11-22 | $11.71 | $498K | -0.3% | +0.7% | +3.6% |
| CTMX | SELL | 2016-11-17 | 2016-11-21 | $11.61 | $526K | -7.6% | -3.3% | +0.3% |
| CTMX | SELL | 2016-11-15 | 2016-11-16 | $11.50 | $593K | -1.5% | +6.0% | +2.8% |
| CTMX | SELL | 2016-11-10 | 2016-11-14 | $11.16 | $1.9M | +4.2% | +1.1% | +2.6% |
| CTMX | SELL | 2016-06-10 | 2016-06-10 | $10.01 | $27K | -6.4% | +4.5% | +26.5% |
| CTMX | SELL | 2016-06-06 | 2016-06-08 | $10.01 | $1.1M | -5.9% | +6.8% | +27.8% |
| CTMX | SELL | 2016-06-02 | 2016-06-06 | $10.80 | $644K | +1.3% | +2.4% | +29.2% |
| CTMX | SELL | 2016-06-01 | 2016-06-02 | $10.75 | $241K | -7.1% | -7.6% | +8.1% |
| CTMX | SELL | 2016-05-24 | 2016-05-25 | $10.00 | $12K | +0.3% | -1.3% | +18.7% |
| CTMX | SELL | 2016-05-19 | 2016-05-23 | $10.14 | $25K | +8.4% | -5.1% | +11.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.